Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

1. Herbst, R.S.
2. Garon, E.B.
3. Kim, D.-W.
4. Cho, B.C.
5. Gervais, R.
6. Perez-Gracia, J.L.
7. Han, J.-Y.
8. Majem, M.
9. Forster, M.D.
10. Monnet, I.
11. Novello, S.
12. Gubens, M.A.
13. Boyer, M.
14. Su, W.-C.
15. Samkari, A.
16. Jensen, E.H.
17. Kobie, J.
18. Piperdi, B.
19. Baas, P.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.JTHO.2021.05.001 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus